Literature DB >> 27280504

The Impact of Adjuvant Postoperative Radiation Therapy and Chemotherapy on Survival After Esophagectomy for Esophageal Carcinoma.

Andrew T Wong1, Meng Shao, Justin Rineer, Anna Lee, David Schwartz, David Schreiber.   

Abstract

OBJECTIVE: The objective of this study was to analyze the impact on overall survival (OS) from the addition of postoperative radiation with or without chemotherapy after esophagectomy, using a large, hospital-based dataset.
BACKGROUND: Previous retrospective studies have suggested an OS advantage for postoperative chemoradiation over surgery alone, although prospective data are lacking.
METHODS: The National Cancer Data Base was queried to select patients diagnosed with stage pT3-4Nx-0M0 or pT1-4N1-3M0 esophageal carcinoma (squamous cell or adenocarcinoma) from 1998 to 2011 treated with definitive esophagectomy ± postoperative radiation and/or chemotherapy. OS was analyzed using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox regression analysis was used to identify covariates associated with OS.
RESULTS: There were 4893 patients selected, of whom 1153 (23.6%) received postoperative radiation. Most patients receiving radiation also received sequential/concomitant chemotherapy (89.9%). For the entire cohort, postoperative radiation was associated with a statistically significant but modest absolute improvement in survival (hazard ratio 0.77; 95% CI, 0.71-0.83; P < 0.001). On subgroup analysis, postoperative radiation was associated with improved OS for patients with node-positive disease (3-yr OS 34.3 % vs 27.8%, P < 0.001) or positive margins (3-yr OS 36.4% vs 18.0%, P < 0.001). When chemotherapy usage was incorporated, sequential chemotherapy was associated with the best survival (P < 0.001). Multivariate analysis revealed that the addition of chemotherapy to radiation therapy, whether sequentially or concurrently, was a strong prognostic factor for OS.
CONCLUSIONS: In this hospital-based study, the addition of postoperative chemoradiation (either sequentially or concomitantly) after esophagectomy was associated with improved OS for patients with node-positive disease or positive margins.

Entities:  

Mesh:

Year:  2017        PMID: 27280504     DOI: 10.1097/SLA.0000000000001825

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma.

Authors:  H Luo; Y Y Cui; J G Zhang; Y N Sun; X L Zheng; C L Yang; K Ye; H Ge
Journal:  Clin Transl Oncol       Date:  2017-11-15       Impact factor: 3.405

2.  Do we have enough evidence for adjuvant postoperative chemoradiation in esophageal cancer?

Authors:  Po-Kuei Hsu
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

3.  A retrospective study of pattern of recurrence after radical surgery for thoracic esophageal carcinoma with or without postoperative radiotherapy.

Authors:  Yichun Wang; Li Zhang; Dongmei Ye; Wanli Xia; Jun Jiang; Xiumei Wang; Mingxia Zhang; Fan Wang
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

4.  Adjuvant radiotherapy in oesophageal cancer with positive circumferential resection margins-recurrence and survival outcomes.

Authors:  Bhamini Vadhwana; Dimitrios Zosimas; Panagis M Lykoudis; Huan Ming Phen; Maria Martinou; Thangadorai Amalesh; David Khoo
Journal:  J Gastrointest Oncol       Date:  2019-06

5.  Adjuvant therapy for pathological T3N0M0 esophageal squamous cell carcinoma.

Authors:  Xiaobin Zhang; Yu Yang; Yifeng Sun; Bo Ye; Xufeng Guo; Teng Mao; Rong Hua; Bin Li; Haiyong Gu; Jun Liu; Zhigang Li
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

Review 6.  Is endoscopic ultrasound examination necessary in the management of esophageal cancer?

Authors:  Tomas DaVee; Jaffer A Ajani; Jeffrey H Lee
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

7.  The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa-IVa lower thoracic oesophageal squamous cell carcinoma.

Authors:  Yichun Wang; Liyang Zhu; Wanli Xia; Liming Wu; Fan Wang
Journal:  World J Surg Oncol       Date:  2018-11-07       Impact factor: 2.754

8.  Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.

Authors:  Wei Deng; Jinsong Yang; Wenjie Ni; Chen Li; Xiao Chang; Weiming Han; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Nan Bi; Tao Zhang; Yexiong Li; Shugeng Gao; Qi Xue; Yousheng Mao; Kelin Sun; Xiangyang Liu; Dekang Fang; Dali Wang; Jian Li; Jun Zhao; Kang Shao; Zhishan Li; Xinjie Chen; Lei Han; Lifang Wang; Jie He; Zefen Xiao
Journal:  Oncologist       Date:  2020-02-21

9.  Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial.

Authors:  Wenjie Ni; Shufei Yu; Zefen Xiao; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Shugeng Gao; Yousheng Mao; Qi Xue; Kelin Sun; Xiangyang Liu; Dekang Fang; Jian Li; Dali Wang; Jun Zhao; Yushun Gao
Journal:  Oncologist       Date:  2021-08-19

10.  Salvage radiochemotherapy for lymph node recurrence after radical surgery of esophageal cancer.

Authors:  Yi-Qin Zhou; Nai-Xin Ding; Li-Jun Wang; Wei Liu; Ming Jiang; Jin-Cheng Lu
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.